Ukrainian intelligence has identified at least 18 US citizens who signed contracts with the Russian army. Propaganda channels promise them significant financial payments, although some have already died on the battlefield.
Odoxa-Mascaret poll records historically lowest support for the French president, while National Rally leaders maintain 35% standing.
Fire Point co-founder Iryna Terekh registered the MILFtech trademark in her personal name, sparking a backlash. Meanwhile, Denys Shchiterman has again postponed the delivery of long-range weapons despite significant state funding.
Police and SBU exposed a 35-year-old Lviv resident who sold cocaine and MDMA. He faces up to 12 years in prison.
Following criticism of a June procurement that favoured a single brand, the DPA optimised technical conditions. This allowed it to order 130 units of equipment for UAH 61m less than in the previous tender.
Details of Leonid Titarenko's career, who is responsible for the security of the People's Deputy, include a criminal past, involvement in a shootout, and joint companies with the politician.
The musician is attempting to remove inconvenient publications from the internet by pressuring platforms to delete content through formal but false claims.
According to the Telegram channel Buddha from OP, Yulia Myronova started working at the Kyiv office of Maxi Group as a shift supervisor, a role involving the monitoring of call centre operators.
Iosif Kobzon has died at the age of 81. The artist was diagnosed with cancer. He underwent treatment abroad and in Russia for an extended period.
Several weeks ago, Kobzon was hospitalised in an unconscious state at one of Moscow’s clinics, where he was connected to life-support machines.
At that point, doctors stated that the artist was unlikely to return home. However, his family refused to believe in such an outcome and insisted to the press that the hospitalisation was a routine check-up and that Kobzon’s life was not in danger.
It was announced today that Iosif Kobzon has died.
Comments
No comments yet. Be the first!